Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer (Q33208591)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

23 July 2017

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer (English)

1 reference

Europe PubMed Central

23 July 2017

prostate cancer

1 reference

based on heuristic

inferred from title

object named as

T Demkow

8

0 references

author name string

R P Abratt

1

1 reference

Europe PubMed Central

23 July 2017

D Brune

2

1 reference

Europe PubMed Central

23 July 2017

M-A Dimopoulos

3

1 reference

Europe PubMed Central

23 July 2017

J Kliment

4

1 reference

Europe PubMed Central

23 July 2017

J Breza

5

1 reference

Europe PubMed Central

23 July 2017

F P Selvaggi

6

1 reference

Europe PubMed Central

23 July 2017

P Beuzeboc

7

1 reference

Europe PubMed Central

23 July 2017

S Oudard

9

1 reference

Europe PubMed Central

23 July 2017

publication date

1 November 2004

1 reference

Europe PubMed Central

23 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

23 July 2017

15

1 reference

Europe PubMed Central

23 July 2017

1613-1621

1 reference

Europe PubMed Central

23 July 2017

11

1 reference

Europe PubMed Central

23 July 2017

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Phase II study of vinorelbine in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

The Measurement of Observer Agreement for Categorical Data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Epothilones: mechanism of action and biologic activity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH429

21 January 2018

Identifiers

10.1093/ANNONC/MDH429

1 reference

Europe PubMed Central

23 July 2017

1 reference

Europe PubMed Central

23 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33208591&oldid=1966956490"